Jan 4 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS OF NETARSUDIL OPHTHALMIC SOLUTION IN PILOT PHASE 2 STUDY SUPPORTING CLINICAL DEVELOPMENT IN JAPAN.AERIE PHARMACEUTICALS INC - ANNOUNCES OPENING OF TOKYO BRANCH OFFICE.AERIE PHARMACEUTICALS INC - AERIE EXPECTS TO INITIATE A PHASE 2 CLINICAL TRIAL IN JAPAN IN Q1 OF 2019.AERIE PHARMA - NETARSUDIL REDUCED PRESSURES IN LOWER-BASELINE SUBJECTS AT CONSISTENT LEVELS TO WHAT WAS DEMONSTRATED IN PHASE 3 TRIALS IN U.S..
Full Article
Nov 6 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 ADJUSTED LOSS PER SHARE $1.73.Q3 GAAP LOSS PER SHARE $1.96.Q3 EARNINGS PER SHARE VIEW $-1.38 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 SALES $20 MILLION TO $30 MILLION.QTRLY TOTAL NET REVENUE $7.3 MILLION.Q3 REVENUE VIEW $5.9 MILLION -- THOMSON REUTERS I/B/E/S.PLANS TO BRING TWO SUSTAINED-RELEASE RETINA PRODUCT CANDIDATES INTO CLINIC IN 2019.
Full Article
Sept 12 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS - APPROVED INCREASE IN SIZE OF AUDIT COMMITTEE OF BOARD FROM 3 TO 4 MEMBERS - SEC FILING.
Full Article
May 8 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 ADJUSTED LOSS PER SHARE $0.83.Q1 GAAP LOSS PER SHARE $1.05.Q1 EARNINGS PER SHARE VIEW $-0.87 -- THOMSON REUTERS I/B/E/S.
Full Article
Feb 28 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE AND 2018 GUIDANCE.Q4 ADJUSTED LOSS PER SHARE $1.38.Q4 GAAP LOSS PER SHARE $1.60.EXPECTS CASH BURN FOR FULL YEAR 2018 IN RANGE OF $200 MILLION TO $210 MILLION.
Full Article
Jan 24 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.AERIE PHARMACEUTICALS INC - PRICED ITS REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF SHARES OF ITS COMMON STOCK.
Full Article
Dec 19 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING.AERIE PHARMACEUTICALS - PURSUANT TO AGREEMENT, CO MAY OFFER AND SELL SHARES, PAR VALUE $0.001 PER SHARE, HAVING OFFERING PRICE OF UP TO $75 MILLION.
Full Article
Dec 18 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE LOWERING OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - REMAIN ON TRACK TO FILE ROCLATAN NEW DRUG APPLICATION TO FDA IN Q2 2018.AERIE PHARMACEUTICALS - RHOPRESSA APPROVED AHEAD OF SCHEDULED PDUFA DATE OF FEBRUARY 28, 2018.
Full Article
Nov 16 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan.Aerie Pharmaceuticals Inc - for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018.
Full Article
Nov 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 adjusted loss per share $0.71.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Q3 gaap loss per share $0.89.Aerie Pharmaceuticals Inc - as of september 30, 2017, Aerie had $282.2 million in cash, cash equivalents and investments.
Full Article
Earnings vs. 
Estimates